Sato Vicki L insider trades
Sato Vicki L has filed 71 Form 4s with the SEC that we hold, for Vir Biotechnology, Inc. (VIR) (Director), Denali Therapeutics Inc. (DNLI) (Director), Allogene Therapeutics, Inc. (ALLO) (Director) and AKUS (Director). Across all of them we count 0 purchases worth $0 and 82 sales worth $13.9M reported on Form 4. In the last 12 months: 0 purchases ($0) and 10 sales ($1.6M). The largest single trade was a sale of 11,775 shares of Vir Biotechnology, Inc. worth $616.0K, dated 2021-09-17. The first filing on our record is dated 2021-07-20 and the latest 2026-06-23.
Vir Biotechnology, Inc. (VIR)
Director · 37 filings · 48 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-19 | S, sale reported on Form 4 | 8,811 | $323.7K | 2021-07-20 |
| 2021-07-19 | S, sale reported on Form 4 | 6,363 | $240.8K | 2021-07-20 |
| 2021-08-19 | S, sale reported on Form 4 | 6,129 | $271.9K | 2021-08-23 |
| 2021-08-19 | S, sale reported on Form 4 | 9,045 | $411.7K | 2021-08-23 |
| 2021-09-17 | S, sale reported on Form 4 | 3,399 | $180.4K | 2021-09-21 |
| 2021-09-17 | S, sale reported on Form 4 | 11,775 | $616.0K | 2021-09-21 |
| 2021-10-19 | S, sale reported on Form 4 | 8,503 | $339.4K | 2021-10-20 |
| 2021-10-19 | S, sale reported on Form 4 | 6,671 | $261.0K | 2021-10-20 |
| 2021-11-26 | S, sale reported on Form 4 | 15,174 | $558.4K | 2021-11-30 |
| 2021-12-20 | S, sale reported on Form 4 | 5,173 | $268.3K | 2021-12-21 |
| 2021-12-20 | S, sale reported on Form 4 | 1,300 | $70.7K | 2021-12-21 |
| 2021-12-20 | S, sale reported on Form 4 | 2,401 | $138.8K | 2021-12-21 |
| 2021-12-20 | S, sale reported on Form 4 | 1,100 | $61.7K | 2021-12-21 |
| 2021-12-20 | S, sale reported on Form 4 | 5,200 | $288.0K | 2021-12-21 |
| 2022-01-18 | S, sale reported on Form 4 | 15,173 | $567.3K | 2022-01-20 |
| 2022-04-28 | S, sale reported on Form 4 | 3,822 | $82.1K | 2022-05-02 |
| 2022-04-28 | S, sale reported on Form 4 | 14,093 | $292.3K | 2022-05-02 |
| 2022-05-09 | S, sale reported on Form 4 | 14,541 | $299.8K | 2022-05-10 |
| 2022-05-24 | S, sale reported on Form 4 | 3,374 | $80.4K | 2022-05-25 |
| 2022-06-08 | S, sale reported on Form 4 | 17,415 | $449.7K | 2022-06-09 |
| 2022-06-08 | S, sale reported on Form 4 | 500 | $13.3K | 2022-06-09 |
| 2022-07-08 | S, sale reported on Form 4 | 12,843 | $370.8K | 2022-07-12 |
| 2022-07-08 | S, sale reported on Form 4 | 5,072 | $150.0K | 2022-07-12 |
| 2022-08-08 | S, sale reported on Form 4 | 17,915 | $542.6K | 2022-08-09 |
| 2022-09-08 | S, sale reported on Form 4 | 17,915 | $392.3K | 2022-09-09 |
| 2022-10-10 | S, sale reported on Form 4 | 17,915 | $370.3K | 2022-10-11 |
| 2022-11-08 | S, sale reported on Form 4 | 17,915 | $490.5K | 2022-11-09 |
| 2022-12-08 | S, sale reported on Form 4 | 17,915 | $462.4K | 2022-12-09 |
| 2023-01-09 | S, sale reported on Form 4 | 17,915 | $462.7K | 2023-01-11 |
| 2023-02-08 | S, sale reported on Form 4 | 17,288 | $490.1K | 2023-02-09 |
| 2023-02-08 | S, sale reported on Form 4 | 627 | $18.2K | 2023-02-09 |
| 2023-03-08 | S, sale reported on Form 4 | 17,935 | $405.2K | 2023-03-09 |
| 2023-06-30 | S, sale reported on Form 4 | 18,000 | $443.9K | 2023-07-03 |
| 2025-01-08 | S, sale reported on Form 4 | 10,960 | $137.2K | 2025-01-08 |
| 2025-07-01 | S, sale reported on Form 4 | 22,000 | $112.2K | 2025-07-02 |
| 2025-08-01 | S, sale reported on Form 4 | 22,000 | $109.8K | 2025-08-04 |
| 2025-09-02 | S, sale reported on Form 4 | 22,000 | $109.8K | 2025-09-03 |
| 2025-10-01 | S, sale reported on Form 4 | 22,000 | $128.5K | 2025-10-02 |
| 2025-11-03 | S, sale reported on Form 4 | 22,000 | $124.1K | 2025-11-04 |
| 2025-12-01 | S, sale reported on Form 4 | 22,000 | $132.0K | 2025-12-02 |
| 2026-01-02 | S, sale reported on Form 4 | 22,000 | $130.5K | 2026-01-05 |
| 2026-02-02 | S, sale reported on Form 4 | 22,000 | $169.6K | 2026-02-03 |
| 2026-02-24 | S, sale reported on Form 4 | 42,177 | $411.2K | 2026-02-26 |
| 2026-02-24 | S, sale reported on Form 4 | 200 | $2.1K | 2026-02-26 |
| 2026-03-02 | S, sale reported on Form 4 | 200 | $2.0K | 2026-03-03 |
| 2026-03-02 | S, sale reported on Form 4 | 21,800 | $207.1K | 2026-03-03 |
| 2026-04-01 | S, sale reported on Form 4 | 22,000 | $199.5K | 2026-04-02 |
| 2026-05-01 | S, sale reported on Form 4 | 22,000 | $221.1K | 2026-05-04 |
Denali Therapeutics Inc. (DNLI)
Director · 26 filings · 34 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-21 | S, sale reported on Form 4 | 400 | $25.7K | 2021-07-23 |
| 2021-07-21 | S, sale reported on Form 4 | 866 | $56.5K | 2021-07-23 |
| 2021-07-21 | S, sale reported on Form 4 | 400 | $26.3K | 2021-07-23 |
| 2021-08-18 | S, sale reported on Form 4 | 806 | $41.3K | 2021-08-20 |
| 2021-08-18 | S, sale reported on Form 4 | 860 | $44.8K | 2021-08-20 |
| 2021-09-15 | S, sale reported on Form 4 | 230 | $12.0K | 2021-09-17 |
| 2021-09-15 | S, sale reported on Form 4 | 140 | $7.7K | 2021-09-17 |
| 2021-09-15 | S, sale reported on Form 4 | 620 | $33.4K | 2021-09-17 |
| 2021-09-15 | S, sale reported on Form 4 | 676 | $35.8K | 2021-09-17 |
| 2021-11-01 | S, sale reported on Form 4 | 1,666 | $83.4K | 2021-11-03 |
| 2021-11-10 | S, sale reported on Form 4 | 1,006 | $52.8K | 2021-11-12 |
| 2021-11-10 | S, sale reported on Form 4 | 660 | $35.2K | 2021-11-12 |
| 2023-06-28 | S, sale reported on Form 4 | 552 | $16.3K | 2023-06-30 |
| 2023-06-28 | S, sale reported on Form 4 | 1,114 | $33.4K | 2023-06-30 |
| 2023-07-17 | S, sale reported on Form 4 | 1,666 | $49.3K | 2023-07-19 |
| 2023-08-15 | S, sale reported on Form 4 | 1,666 | $40.5K | 2023-08-17 |
| 2023-09-15 | S, sale reported on Form 4 | 1,626 | $38.4K | 2023-09-19 |
| 2023-09-15 | S, sale reported on Form 4 | 40 | $974 | 2023-09-19 |
| 2023-10-16 | S, sale reported on Form 4 | 1,666 | $34.4K | 2023-10-18 |
| 2023-11-15 | S, sale reported on Form 4 | 1,666 | $31.9K | 2023-11-16 |
| 2023-12-15 | S, sale reported on Form 4 | 1,666 | $39.0K | 2023-12-18 |
| 2024-01-16 | S, sale reported on Form 4 | 1,666 | $30.7K | 2024-01-18 |
| 2024-02-15 | S, sale reported on Form 4 | 1,666 | $30.6K | 2024-02-20 |
| 2024-03-15 | S, sale reported on Form 4 | 1,666 | $33.5K | 2024-03-19 |
| 2024-04-15 | S, sale reported on Form 4 | 1,666 | $30.5K | 2024-04-17 |
| 2024-05-15 | S, sale reported on Form 4 | 1,674 | $34.1K | 2024-05-17 |
| 2024-07-01 | S, sale reported on Form 4 | 100 | $2.3K | 2024-07-03 |
| 2024-07-01 | S, sale reported on Form 4 | 2,980 | $65.9K | 2024-07-03 |
| 2024-09-03 | S, sale reported on Form 4 | 2,980 | $74.5K | 2024-09-04 |
| 2024-09-03 | S, sale reported on Form 4 | 100 | $2.5K | 2024-09-04 |
| 2024-09-13 | S, sale reported on Form 4 | 1,020 | $30.6K | 2024-09-16 |
| 2024-11-01 | S, sale reported on Form 4 | 3,080 | $83.4K | 2024-11-05 |
| 2024-11-07 | S, sale reported on Form 4 | 1,020 | $30.6K | 2024-11-12 |
| 2025-01-02 | S, sale reported on Form 4 | 3,080 | $64.4K | 2025-01-03 |
Allogene Therapeutics, Inc. (ALLO)
Director · 6 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
AKUS
Director · 2 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1197020) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms